| Abstrakt: |
The early pathogenetic mechanism of diabetic retinopathy (DR) and its treatment remain unclear. Therefore, we used streptozotocin-induced diabetic mice to investigate the early pathogenic alterations in DR and the protective effect of sodium–glucose cotransporter 2 (SGLT2) inhibitors against these alterations. Retinal vascular leakage was assessed by dextran fluorescence angiography. Retinal thickness and vascular leakage were increased 2 and 4 weeks after onset of diabetes, respectively. Immunostaining showed that morphological change of microglia (amoeboid form) was observed at 2 weeks. Subsequently, increased angiopoietin-2 expression, simultaneous loss of pericytes and endothelial cells, decreased vessel density, retinal hypoxia, and increased vascular endothelial growth factor (VEGF)-A/VEGF receptor system occurred at 4 weeks. SGLT2 inhibitors (luseogliflozin and ipragliflozin) had a significant protective effect on retinal vascular leakage and retinal thickness at a low dose that did not show glucose-lowering effects. Furthermore, both inhibitors at this dose attenuated microglia morphological changes and these early pathogenic alterations in DR. In vitro study showed both inhibitors attenuated the lipopolysaccharide-induced activation of primary microglia, along with morphological changes toward an inactive form, suggesting the direct inhibitory effect of SGLT2 inhibitors on microglia. In summary, SGLT2 inhibitors may directly prevent early pathogenic mechanisms, thereby potentially playing a role in preventing DR. Article Highlights: We used streptozotocin-induced diabetic mice to investigate the early pathogenic alterations in diabetic retinopathy (DR) and the protective effect of sodium–glucose cotransporter 2 inhibitors (SGLT2i) against these alterations. SGLT2i had a significant protective effect on retinal vascular leakage and retinal thickness at a low dose that did not show glucose-lowering effects. SGLT2i at this dose attenuated early pathogenic alterations, including microglia morphological changes, increased angiopoietin-2 expression, and decreased vessel density and hypoxia induced by diabetes. SGLT2i may break an early pathogenic vicious cycle and exert protective effects against DR. [ABSTRACT FROM AUTHOR] |
